Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBIT (2023 - 2024)

Historic EBIT for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to -$17.0 million.

  • Contineum Therapeutics' EBIT fell 7617.82% to -$17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$50.9 million, marking a year-over-year decrease of 41657.03%. This contributed to the annual value of -$50.9 million for FY2024, which is 41656.4% down from last year.
  • Contineum Therapeutics' EBIT amounted to -$17.0 million in Q4 2024, which was down 7617.82% from -$13.0 million recorded in Q3 2024.
  • Over the past 5 years, Contineum Therapeutics' EBIT peaked at $38.9 million during Q2 2023, and registered a low of -$17.0 million during Q4 2024.